Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoblituzumab combinations in SCCHN
NCT04129320Phase 3Withdrawn
- Sponsor
- MacroGenics
- Start
- Oct 2019
- Primary completion
- Oct 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, open-label trial of enoblituzumab in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by MacroGenics. Primary endpoints: Overall Response Rate at 2 years and Incidence of Adverse Events. Planned start Oct 2019; status: withdrawn.
02
Drugs
enoblituzumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04129320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129320.